{"id":"W2214943066","doi":"10.14740/jocmr2424w","title":"Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma","year":2015,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":59,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Dabrafenib; Vemurafenib; Medicine; Ipilimumab; Trametinib; Nivolumab; Pembrolizumab; Targeted therapy; Melanoma; Metastatic melanoma; MAPK/ERK pathway; Adverse effect; Combination therapy; Oncology; Immune checkpoint; Cancer research; Immunotherapy; Cancer; Pharmacology; Internal medicine; Kinase","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008607851,0.0001654671,0.001529554,0.0001385011,0.00005348046,0.000009154995,0.0002963193,0.0001892615,0.000007781447],"category_scores_gemma":[0.00235269,0.00007187459,0.000412489,0.0001141349,0.0004801527,0.000002690098,0.00004426648,0.0002866426,7.031212e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002209452,"about_ca_system_score_gemma":0.0007147044,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001099126,"about_ca_topic_score_gemma":0.000003269857,"domain_scores_codex":[0.9970842,0.0006184974,0.001391826,0.0001796662,0.0005460539,0.0001797582],"domain_scores_gemma":[0.9944137,0.003301886,0.0008607868,0.0002865826,0.0009711545,0.0001658596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001738423,0.0003493252,0.00001240564,0.001177417,0.0008014704,0.0000032411,0.0001183478,6.317222e-8,0.0000617538,0.0001693873,0.003072112,0.9940606],"study_design_scores_gemma":[0.002540838,0.01642897,0.00002043859,0.001186761,0.0006602011,0.00007243925,0.0002459087,0.000005926646,0.00003811642,0.0002714052,0.9784679,0.0000610506],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007036517,0.9969574,0.0003992205,0.0006444565,0.0003922674,0.0007226306,0.00002401971,6.66531e-7,0.0001557462],"genre_scores_gemma":[0.0005405079,0.9971113,0.0004067767,0.00001554326,0.001421392,0.00003590902,0.00002721358,0.00002014001,0.0004211728],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9939996,"threshold_uncertainty_score":0.2983327,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.4573143908375632,"score_gpt":0.5752513556841012,"score_spread":0.117936964846538,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}